Key result
Lipid therapy adjustments link to ~4.6-fold higher 12-month persistence despite widespread clinical inertia.
Why the study?
What are the 12-month persistence, LDL-C target effectiveness, and clinical inertia rates among patients initiating lipid-lowering therapy for dyslipidemia in the Colombian healthcare system?
Cohort (n=381)
Yes
What are the 12-month persistence, LDL-C target effectiveness, and clinical inertia rates among patients initiating lipid-lowering therapy for dyslipidemia in the Colombian healthcare system?
Answers are grounded in this paper and cite their sources.
In real-world Colombian practice, fewer than one-third of dyslipidemia patients achieved guideline LDL-C targets at one year, driven heavily by clinical inertia (52.0%) and suboptimal treatment persistence (58.3%).
Introduction: Lipid-lowering therapy reduces the risk of atherosclerotic cardiovascular disease, but effectiveness may depend on persistence, adherence, and clinical inertia.Objective: To determine the persistence of use, effectiveness, and clinical inertia of lipid-lowering therapy in a group of patients with dyslipidemia enrolled in the Colombian healthcare system.Methods: This was an observational, retrospective, longitudinal study of patients diagnosed with dyslipidemia enrolled in the Colombian healthcare system.Sociodemographic, clinical (cardiovascular risk) and pharmacological variables were identified.The effectiveness of the treatment, presence of clinical inertia, and persistence of use were determined.Results: A total of 381 patients were analyzed, with a median age of 61.0 years; 63.5% were women.Forty-two percent of the patients had high or very high cardiovascular risk and were treated mainly with statins (83.7%).A total of 31.5% reached the treatment goal, and 52.0% of those who did not achieve control had clinical inertia.A total of 58.3% persisted with lipid-lowering therapy at 12 months, and having a high or very high cardiovascular risk (OR:1.81;95% CI:1.05-3.10),receiving comedications (OR:2.06;95% CI:1.01-4.17),and having treatment adjustments (OR:4.56;95% CI:2.60-7.99)were associated with a higher likelihood of persistence.Conclusions: Identifying the effectiveness, clinical inertia and persistence of the use of lipid-lowering drugs in each group of treated patients should help make the necessary adjustments to achieve the goals and guarantee adherence to treatment.
No takes yet. Share an insight, caveat, or question.
Valladales-Restrepo et al. (2026) conducted a cohort in Dyslipidemia (n=381). Lipid-lowering therapy (predominantly statins, 83.7%, alongside fibrates and ezetimibe) was evaluated on Persistence with lipid-lowering therapy at 12 months (associated with treatment adjustments) (OR 4.56, 95% CI 2.60-7.99, p=<0.001). Lipid-lowering therapy achieved 58.3% persistence at 12 months and 31.5% LDL-C goal attainment, with 52.0% of uncontrolled patients experiencing clinical inertia.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: